

Anti-CTLA-4 (Tremelimumab), Human IgG2 Antibody

07/20

CATALOG NO.: A2163-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a fully-humanized IgG2 monoclonal antibody that binds to human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on the activated T cells. Binding to CTLA-4 results in inhibition of its association with the ligands B7-1 (CD80) and B7-2 (CD86), thereby preventing the downregulation of T-cell activation and inhibition of tumor growth. The original drug is currently undergoing clinical trials for the treatment of several cancers such as melanoma, mesothelioma and non-small cell lung cancer

ALTERNATE NAMES: CP-675, CP-675,206, CP-675206 clone 11.2.1, CD; GSE; GRD4; ALPS5; CD152; CTLA4; IDDM12; CELIAC3

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG2, kappa

SOURCE: CHO cells

IMMUNOGEN: Human CTLA-4

CAS NUMBER: 745013-59-6

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-CTLA-4 (Ipilimumab), Humanized Antibody (A2110)
 Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)
 Anti-PD-L1 (Durvalumab), Human IgG1 Antibody (A2109)
 Anti-PD-L1 (Avelumab), Human IgG1 Antibody (A2152)
 Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)

FOR RESEARCH USE ONLY! Not to be used on humans.